Advanced HIV (N = 105)a | Non-advanced HIV (N = 852) | p-value | |||
---|---|---|---|---|---|
N | % | N | % | ||
District | < 0.001 | ||||
Kayonza | 34 | 32.4 | 298 | 35.0 | |
Kirehe | 22 | 21.0 | 363 | 42.6 | |
Burera | 49 | 46.7 | 191 | 22.4 | |
Age at baseline | < 0.001 | ||||
15–24 | 13 | 12.4 | 187 | 22.0 | |
25–34 | 19 | 18.1 | 324 | 38.0 | |
35–44 | 32 | 30.5 | 179 | 21.0 | |
≥ 45 | 41 | 39.1 | 162 | 19.0 | |
Sex | 0.090 | ||||
Female | 61 | 58.1 | 566 | 66.4 | |
Male | 44 | 41.9 | 286 | 33.6 | |
Distance to health facility (km) | 0.300 | ||||
0–2 | 19 | 18.1 | 221 | 25.9 | |
> 2–5 | 42 | 40.0 | 308 | 36.2 | |
> 5 | 23 | 21.9 | 188 | 22.1 | |
Missing | 21 | 20.0 | 135 | 15.9 | |
BMI categoryc | < 0.001 | ||||
< 16 | 9 | 8.6 | 13 | 1.5 | |
16–18.5 | 13 | 12.4 | 69 | 8.1 | |
> 18.5 | 40 | 38.1 | 443 | 52.0 | |
Missing | 43 | 41.0 | 327 | 38.4 | |
WHO stage | < 0.001b | ||||
Stage1 | 25 | 23.8 | 713 | 83.7 | |
Stage2 | 9 | 8.6 | 86 | 10.1 | |
Stage3 | 48 | 45.7 | 0 | 0.0 | |
Stage4 | 11 | 10.5 | 0 | 0.0 | |
Missing | 12 | 11.4 | 53 | 6.2 | |
CD4 count (cells/mm3) | < 0.001b | ||||
< 200 | 61 | 58.1 | 0 | 0.0 | |
200–350 | 6 | 5.7 | 64 | 7.5 | |
351–499 | 4 | 3.8 | 64 | 7.5 | |
500 and above | 2 | 1.9 | 189 | 22.2 | |
Missing | 32 | 30.5 | 535 | 62.8 | |
Method of enrollment | < 0.001b | ||||
VCTc | 20 | 19.1 | 338 | 39.7 | |
PMTCTc | 1 | 1.0 | 102 | 12.0 | |
Inpatient or tuberculosis | 11 | 10.5 | 10 | 1.2 | |
Outpatient | 15 | 14.3 | 70 | 8.2 | |
Other/missing | 58 | 55.2 | 332 | 39.0 |